Chromatin, metabolism and cell fate


Myeloid neoplasms

Applied Epigenetcs

Belongs to

IJC Can Ruti



We focus on understanding the molecular aspects of chromatin regulation and have a long-standing interest in the study of histone variants. We want to find ways to translate knowledge about chromatin regulation into therapeutic tools for the management of diseases such as blood cancers.


We seek to bridge the gap between basic molecular research and translational research by exploring chromatin regulation, in particular the molecular biology of histone variants. We aim to exploit this knowledge for the identification of novel intervention strategies for the treatment of blood cancers. We focus on the continuum of myeloid diseases, ranging from the premalignant expansion of altered clones to chronic myelodysplastic syndromes and acute myeloid leukaemia.



Through our research, we aim to gain a better understanding of the epigenetic mechanisms that contribute to the development of blood cancers. By functionally mining the chromatin regulatory space, we further aim to provide new starting points by identifying novel drug targets. In this regard, our research focuses on two main lines:

1.     To mine the chromatin regulatory space to identify novel drug targets that can either help improve current treatments or intercept disease at an early asymptomatic stage.
2.     We study histones from the protein core of the nucleosome, particularly the variant macroH2A that led to two major discoveries: its major role in nuclear organization and its ability to bind metabolites through its mostly understood macrodomain, establishing a direct link between chromatin and metabolism.


Through our research, we hope to answer the following questions:
1.     How do epigenetic mechanisms operate on the molecular level?
2.     How do chromatin and, in particular, histone variants contribute to cell fate transitions? 
3.     How can we exploit this knowledge for the development of novel therapeutic strategies?


Selected Publications

Current Grants


Fundació la marató de tv3

Explorant i explotant les variants d'histones com a dianes terapèutiques en la leucèmia mieloide aguda


European commission

INTERCEPT-MDS Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.

Centre national de la recherche scientifique

EpiGene3Sys Moving  Epigenetics towards Systems Biology – EpiGene3Sys.

2021 SGR 00260

Agència de gestió d'ajuts universitaris i de recerca

Chromatin, metabolism and cell fate


Ministerio de ciencia, innovación y universidades

Regulacion de la arquitectura tridimensional de la cromatina por parte de las variantes de histona macroh2a y su capacidad de unir metabolitos.


European commission

CarrerasLeaders Carreras Postdoc Program Empowering Future Leaders to Fight Blood Cancers